Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Ahmed Maged, Cairo, Egypt
Tampere University Hospital, Tampere, Finland
Sheba medical center, Ramat Gan, Israel
Jazrawi-Atallah, P.C., Brooklyn, New York, United States
Albemarle Urology Clinic, PA, Albemarle, North Carolina, United States
Raj P. Chopra MD, PC, Bloomsburg, Pennsylvania, United States
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
BC CANCER Vancouver, Vancouver, British Columbia, Canada
CancerCare Manitoba, Winnipeg, Manitoba, Canada
Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
Kasr el aini hospital, Cairo, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.